CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 41 enrolled
Drug / intervention
GSK1358820drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01584843
NCT01584843Phase 3Completed
CompareCT.gov

A Multicenter, Randomized, Evaluator-masked, Parallel-group, Non-treatment-controlled Study Followed by an Open-label Study to Evaluate Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus

GlaxoSmithKline·interventional·Posted Apr 25, 2012·Updated Jul 24, 2015

In Brief

A Phase 3 clinical trial evaluating GSK1358820 for Strabismus. Completed, enrolled 41 participants across 13 sites.

Detailed Summary

Primary objective is to evaluate the efficacy of single-dose treatment with GSK1358820 compared with non-treatment in patients with strabismus based on angles of strabismus in the primary position.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStrabismus
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 25, 2012
Enrollment StartMay 1, 2012
Primary CompletionJul 1, 2013
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 14.2 years ago

Interventions

GSK1358820drug

IM injection of Botulinum Toxin Type A